Khan Najat
CIK 2020969
Transactions on file
12
Tickers traded
Recent activity
| Filed | Txn date | Issuer | Roles | Code | Shares | Value | % since Filing | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-09-10 | 2026-09-08 | RXRX RECURSION PHARMACEUTICALS, INC. | OfficerDirector CEO and President | Sale | 22,408 | $78.8K | +1.8% | open → |
| 2026-08-18 | 2026-08-17 | RXRX RECURSION PHARMACEUTICALS, INC. | OfficerDirector CEO and President | Tax | 80,498 | $254.4K | +13.3% | open → |
| 2026-06-05 | 2026-06-05 | RXRX RECURSION PHARMACEUTICALS, INC. | OfficerDirector CEO and President | Sale | 23,588 | $84.5K | -0.0% | open → |
| 2026-05-19 | 2026-05-15 | RXRX RECURSION PHARMACEUTICALS, INC. | OfficerDirector CEO and President | Tax | 62,701 | $190.6K | +17.8% | open → |
| 2025-02-05 | 2025-02-03 | RXRX RECURSION PHARMACEUTICALS, INC. | OfficerDirector Chief R&D Commercial Officer | Grant | 8,049 | $0.00 | — | open → |
| 2025-02-05 | 2025-02-03 | RXRX RECURSION PHARMACEUTICALS, INC. | OfficerDirector Chief R&D Commercial Officer | Grant | 210,113 | $0.00 | — | open → |
| 2025-02-05 | 2025-02-03 | RXRX RECURSION PHARMACEUTICALS, INC. | OfficerDirector Chief R&D Commercial Officer | Tax | 2,753 | $20.0K | -50.6% | open → |
| 2025-05-19 | 2025-05-15 | RXRX RECURSION PHARMACEUTICALS, INC. | OfficerDirector Chief R&D Commercial Officer | Tax | 3,796 | $16.1K | -15.8% | open → |
| 2025-11-19 | 2025-11-17 | RXRX RECURSION PHARMACEUTICALS, INC. | OfficerDirector Chief R&D Commercial Officer | Tax | 17,584 | $72.8K | -13.5% | open → |
| 2025-11-06 | 2025-11-05 | RXRX RECURSION PHARMACEUTICALS, INC. | OfficerDirector Chief R&D Commercial Officer | Grant | 84,925 | $0.00 | — | open → |
| 2025-08-19 | 2025-08-18 | RXRX RECURSION PHARMACEUTICALS, INC. | OfficerDirector Chief R&D Commercial Officer | Sale | 36,599 | $202.0K | -35.1% | open → |
| 2025-08-19 | 2025-08-15 | RXRX RECURSION PHARMACEUTICALS, INC. | OfficerDirector Chief R&D Commercial Officer | Tax | 3,789 | $21.4K | -36.5% | open → |
